Scarica l'app Stockscreener
79.29
1.50%
1.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$78.12
Aprire:
$78.02
Volume 24 ore:
11.90M
Relative Volume:
0.80
Capitalizzazione di mercato:
$199.10B
Reddito:
$63.62B
Utile/perdita netta:
$16.41B
Rapporto P/E:
12.22
EPS:
6.49
Flusso di cassa netto:
$17.04B
1 W Prestazione:
-6.40%
1M Prestazione:
-3.08%
6M Prestazione:
-19.76%
1 anno Prestazione:
-30.34%
Intervallo 1D:
$77.53
$79.87
Intervallo di 1 settimana:
$76.66
$84.97
Portata 52W:
$73.31
$120.30
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer - Insider Monkey
Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewswire Inc.
N.J.-based Merck announces $3B in cost cutting measures including layoffs - NJ.com
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - Insider Monkey
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns - Benzinga
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript - Insider Monkey
Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE - insights.citeline.com
Merck Stock Is Almost A Classical Benjamin Graham Investment - Seeking Alpha
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed - TradingView
Merck will lay off employees and shed some real estate to cut $3 billion in costs - MSN
Earnings call transcript: Merck Q2 2025 beats EPS, stock dips on revenue miss - Investing.com
Why Is Merck Stock Falling On Tuesday?Merck & Co (NYSE:MRK) - Benzinga
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales - AlphaStreet
Merck Cuts $3 Billion in Costs as Keytruda Reign Nears End - MSN
Merck posts Q2 earnings miss, unveils cost-cutting initiative - Proactive financial news
Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms - Bloomberg
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results - Tokenist
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - BioSpace
Merck & Co. Announces New Restructuring Program - TipRanks
Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2 (NYSE:MRK) - Seeking Alpha
Merck plans $3B annual cost cuts as Keytruda faces patent cliff (MRK:NYSE) - Seeking Alpha
Merck & Co Inc. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Merck Q2 Earnings Preview: What to expect? - Seeking Alpha
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings - Benzinga
Merck & Co., Inc. Earnings Preview: Insights and ExpectationsNews and Statistics - IndexBox
Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115 - Insider Monkey
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup - Insider Monkey
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase - MSN
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - MSN
Companion Animal Medicine Market Key Players AnalysisMerck & - openPR.com
Merck Announces Fourth-Quarter 2025 Dividend - BioSpace
Merck Declares $0.81 Per Share Q4 Dividend: Key Dates and Payment Details Revealed - Stock Titan
Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Nasdaq
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects? - 富途牛牛
Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times
Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - MSN
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest
Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey
Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):